Poolbeg Pharma has achieved a significant breakthrough in its artificial intelligence (AI) program through its partnership with medtech company CytoReason. This collaboration, which began in March 2021, involved combining disease progression data from Poolbeg’s influenza human challenge trials with CytoReason’s curated disease data. By analyzing these datasets using CytoReason’s AI-led platform, they were able to identify new drug targets for flu treatment within just 15 months. This is a major advancement compared to the previous manual analysis methods that took several years to identify drug targets.
Currently, Poolbeg Pharma is exploring the development of these new drug targets to bring value to its shareholders. CEO Jeremy Skillington expressed their excitement about being at the forefront of AI drug discovery in collaboration with CytoReason. There is a significant unmet need for better treatments for influenza, as it affects approximately one billion people annually and leads to millions of hospitalizations and hundreds of thousands of deaths.
CytoReason CEO David Harel praised the collaboration, stating that leveraging CytoReason’s computational disease models with Poolbeg’s unique human challenge data optimizes the target discovery process. This successful partnership with CytoReason marks the second AI program for Poolbeg Pharma. In December, the company identified potential drug candidates for respiratory syncytial virus (RSV) infections through its AI program with partner OneThree Biotech. RSV is a respiratory virus that inflames the smallest airways of the lungs and for which there are currently no approved vaccines.
Poolbeg Pharma was spun out from Irish vaccine research company Open Orphan (now known as HVivo) in December 2021.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
